Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) is scheduled to release its earnings data after the market closes on Thursday, November 7th. Analysts expect Allogene Therapeutics to post earnings of ($0.34) per share for the quarter.
Allogene Therapeutics (NASDAQ:ALLO – Get Free Report) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. Allogene Therapeutics had a negative return on equity of 50.24% and a negative net margin of 223,139.98%. On average, analysts expect Allogene Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
Allogene Therapeutics Stock Performance
Shares of NASDAQ ALLO opened at $2.60 on Thursday. The stock has a 50 day moving average price of $2.69 and a 200 day moving average price of $2.69. Allogene Therapeutics has a 52 week low of $2.01 and a 52 week high of $5.78. The stock has a market capitalization of $543.69 million, a PE ratio of -1.64 and a beta of 0.83.
Analyst Ratings Changes
Read Our Latest Stock Analysis on Allogene Therapeutics
Allogene Therapeutics Company Profile
Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL).
Recommended Stories
- Five stocks we like better than Allogene Therapeutics
- Investing In Preferred Stock vs. Common Stock
- Zillow Stock’s Bull Case: Why This Recent Sell-Off Could Be a Buy
- Dividend Capture Strategy: What You Need to Know
- IonQ’s Quantum Surge: Ride the Wave or Cash Out?
- How is Compound Interest Calculated?
- Caterpillar Stock: Market Points to a Buying Opportunity
Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.